Is CeriBell, Inc. (CBLL) a Buy, Sell, or Hold?
NASDAQ : CBLL
CeriBell, Inc.
$17.69 USD
$0.05 (0.28%)
- Volume
- 403.29K
- Average Volume
- 360.6K
- Market Capitalization
- $671.21M
- P/E Ratio
- -10.85
- Dividend Yield
- 0.00%
- Price Target
- $25.00
- Year High
- $24.33
- Year Low
- $10.85
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.30
Company Overview
NASDAQ
Xingjuan Chao
Medical - Devices
Healthcare
CBLL
327
US
USD
Liquidity Metrics
0.16
10.30
9.87
2.80
0.00
Sales & Valuation
$89.06M
7.06
4.73
-13.38
-1.33
Profitability
-$1.46
-$53.41M
-63.51%
-63.51%
-38.19%
-33.90%
P/E Metrics
-10.85
-0.39
-0.39
Analyst Price Target & Rating
$25.00
$25.00
$25.00
2/5
4 Analysts
-29.24%
Financial Health Scores
9.35
1/9
$150.5M
$178.08M
$37.26M
-$58.52M
Key Metrics (TTM)
$648.07M
6.82
-11.32
10.30
-38.19%
-39.83%
-9.06%
-7.47%
214 days
Company Executives
| Name | Title |
|---|---|
| David Foehr | Senior Vice President of Finance |
| Josef Parvizi | Co-Founder, Chief Medical Advisor & Director |
| Raymond Woo | Chief Technology Officer |
| Xingjuan Chao | Co-Founder, President, Chief Executive Officer & Director |
| Brian Price | Senior Vice President of Marketing |
| Dan Rogy | Senior Vice President of Operations |
| Joseph S. Manni | Chief Revenue Officer |
| Baharan Kamousi | Senior Vice President of Data Science |
| Kim McKeon | Vice President of People & Culture |
| Louisa Daniels | General Counsel |
| Scott Blumberg | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About CeriBell, Inc. (NASDAQ:CBLL) Stock
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California. ...
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O'Keefe
2026-07-29 07:00:00
SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointments of Thomas “Tom” West and Sharon O'Keefe to its Board of Directors.
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-07-28 16:05:00
SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston. The fireside chat will take place on Wednesday, August 12, 2026, at 6:00 a.m. Pacific Daylight Time / 9:00 a.m. Eastern Daylight Time.
Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026
2026-07-20 16:05:00
SUNNYVALE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Monday, August 10, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 10, 2026.
2026-06-08 07:00:00
Study published in leading critical care journal shows that higher AI-detected seizure burden is associated with increased odds of disability, further demonstrating the utility of the Ceribell System as a clinical decision-making tool Study published in leading critical care journal shows that higher AI-detected seizure burden is associated with increased odds of disability, further demonstrating the utility of the Ceribell System as a clinical decision-making tool
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
2026-05-20 16:05:00
SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 46th Annual Growth Stock Conference in Chicago. The presentation will take place on Wednesday, June 3, 2026, at 9:20 a.m. Pacific Daylight Time / 11:20 a.m. Central Daylight Time.
CeriBell Sees ‘Early Innings' Growth as Hospital Accounts and Usage Hit Records
2026-05-15 01:07:14
CeriBell NASDAQ: CBLL executives said the company's first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium.
CeriBell, Inc. (CBLL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2026-05-13 20:50:43
CeriBell, Inc. (CBLL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
2026-05-12 09:10:43
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current CeriBell, Inc. (CBLL) stock price?
-
CeriBell, Inc.(NASDAQ:CBLL) stock price is $17.69 in the last trading session. During the trading session, CBLL stock reached the peak price of $24.33 while $10.85 was the lowest point it dropped to. The percentage change in CBLL stock occurred in the recent session was 0.28% while the dollar amount for the price change in CBLL stock was $0.05.
-
CBLL's industry and sector of operation?
-
The NASDAQ listed CBLL is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of CBLL?
-
David Foehr | Senior Vice President of Finance
Josef Parvizi | Co-Founder, Chief Medical Advisor & Director
Raymond Woo | Chief Technology Officer
Xingjuan Chao | Co-Founder, President, Chief Executive Officer & Director
Brian Price | Senior Vice President of Marketing -
How many employees does CBLL have?
-
Number of CBLL employees currently stands at 327. CBLL operates from 360 North Pastoria Avenue, Sunnyvale, CA 94085, US.
-
Link for CBLL official website?
-
Official Website of CBLL is: https://ceribell.com
-
How do I contact CBLL?
-
CBLL could be contacted at phone #800 436 0826 and can also be accessed through its website. CBLL operates from 360 North Pastoria Avenue, Sunnyvale, CA 94085, US.
-
How many shares of CBLL are traded daily?
-
The average number of CBLL shares traded daily for last 3 months was 360.6K.
-
What is the market cap of CBLL currently?
-
The market value of CBLL currently stands at $671.21M with its latest stock price at $17.69